Mucosal immunity

Differences in Sulfotyrosine Binding amongst CXCR1 and CXCR2 Chemokine Ligands

Tyrosine sulfation, a post-translational modification found on many chemokine receptors, typically increases receptor affinity for the chemokine ligand. A previous bioinformatics analysis suggested that a sulfotyrosine (sY)-binding site on the surface of the chemokine CXCL12 may be conserved throughout the chemokine family. However, the extent to which receptor tyrosine sulfation contributes to chemokine binding has been examined in only a few instances. Computational solvent mapping correctly identified the conserved sulfotyrosine-binding sites on CXCL12 and CCL21 detected by nuclear magnetic resonance (NMR) spectroscopy, demonstrating its utility for hot spot analysis in the chemokine family. In this study, we analyzed five chemokines that bind to CXCR2, a subset of which also bind to CXCR1, to identify hot spots that could participate in receptor binding. A cleft containing the predicted sulfotyrosine-binding pocket was identified as a principal hot spot for ligand binding on the structures of CXCL1, CXCL2, CXCL7, and CXCL8, but not CXCL5. Sulfotyrosine titrations monitored via NMR spectroscopy showed specific binding to CXCL8, but not to CXCL5, which is consistent with the predictions from the computational solvent mapping. The lack of CXCL5–sulfotyrosine interaction and the presence of CXCL8–sulfotyrosine binding suggests a role for receptor post-translational modifications regulating ligand selectivity.

Re-considering how particle size and other properties of antigen-adjuvant complexes impact on the immune responses

Understanding the influences of particle properties of antigen-adjuvant complexes on immunity is crucial in designing highly active adjuvants for new-generation of vaccines. This paper briefly revisits the current opinions on the size-dependent immunity of various adjuvant particles and then comprehensively discusses a few immunity-determining processes that are affected by the antigen-adjuvant particle properties. These include particle size, surface charge, surface hydrophilicity/lipophilicity, and antigen-adjuvant binding strength. Based on current understandings, we hypothesize that a maximum immune response occurs at a certain antigen-adjuvant particle size. This hypothesis clearly explains the paradoxical opinions on the size-dependent immunity and has also been supported by the data reported by several research groups. Finally, we further hypothesize that there is a similar relationship between any immune response and any measureable antigen-adjuvant particle property, and that there is a maximum immune response when all measureable antigen-adjuvant particle properties are optimized. We believe more attention should be paid to this issue when designing and developing effective adjuvants in future research.

Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A

Francisella tularensis is an intracellular gram-negative bacterium and the etiological agent of pulmonary tularemia. Given the high degrees of infectivity in the host and of dissemination of bacteria following respiratory infection, immunization strategies that target mucosal surfaces are critical for the development of effective vaccines against this organism. In this study, we have characterized the efficacy of protective immunity against pneumonic tularemia following oral vaccination with F. tularensis LVS (live vaccine strain). Mice vaccinated orally with LVS displayed colocalization of LVS with intestinal M cells, with subsequent enhanced production of splenic antigen-specific gamma interferon and of systemic and mucosal antibodies, including immunoglobulin A (IgA). LVS-vaccinated BALB/c mice were highly protected against intranasal (i.n.) SCHU S4 challenge and exhibited significantly less bacterial replication in the lungs, liver, and spleen than mock-immunized animals. Depletion of CD4(+) T cells significantly abrogated the protective immunity, and mice deficient in B cells or IgA displayed partial protection against SCHU S4 challenge. These results suggest that oral vaccination with LVS induces protective immunity against i.n. challenge with F. tularensis SCHU S4 by a process mediated cooperatively by CD4(+) T cells and antibodies, including IgA.